Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.13865 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic impact of next-generation sequencing on myelodysplastic syndrome: A single-center experience.
Medicine (Baltimore)
October 2024
Hematology Department, İzmir City Hospital, Bayrakli/İzmir, Turkey.
Article Synopsis
- * Recent studies utilizing next-generation sequencing (NGS) have identified numerous genetic abnormalities in patients with MDS, revealing mutations in 21 different genes that could correlate with disease characteristics and clinical outcomes.
- * Findings suggest that certain non-SF3B1 mutations are associated with worse clinical indicators, such as thrombocytopenia and decreased overall survival, indicating that NGS could play a crucial role in future prognostics for MDS, even in patients with normal cytogenetics.
Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
Int J Mol Sci
September 2024
Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Article Synopsis
- Scientists are trying to figure out how to diagnose different types of blood disorders called MDS and MPN, which can be tricky because they have some similar features.
- They looked at the DNA of patients with different types of these disorders to see how they are different and found specific gene mutations that can help identify each type.
- The research shows that age and certain mutations can affect how well patients do, and this information can help doctors make better decisions about treatment.
Prognostic impact of DTA mutation and co-occurring mutations in patients with myelodysplastic syndrome.
Mol Biol Rep
September 2024
Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
Article Synopsis
- This study looked at how common certain gene mutations (DTA genes) are in patients with a blood condition called myelodysplastic syndrome (MDS) and if these mutations affect their health.
- Out of 102 patients tested, most had gene mutations, and more than half had DTA mutations, with some also having other mutations.
- Patients with DTA mutations did not live as long as those without them, especially if they also had a mutation in a gene called RUNX1, but those with another gene called SF3B1 tended to live longer.
Early drivers of clonal hematopoiesis shape the evolutionary trajectories of acute myeloid leukemia.
medRxiv
September 2024
Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Mutations commonly found in AML such as , and can be found in the peripheral blood of otherwise healthy adults - a phenomenon referred to as clonal hematopoiesis (CH). These mutations are thought to represent the earliest genetic events in the evolution of AML. Genomic studies on samples acquired at diagnosis, remission, and at relapse have demonstrated significant stability of CH mutations following induction chemotherapy.
View Article and Find Full Text PDFChronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
Am J Hematol
July 2024
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Chronic neutrophilic leukemia (CNL) is a rare BCR::ABL1-negative myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis and bone marrow granulocyte hyperplasia. Atypical chronic myeloid leukemia (aCML) (myelodysplastic "[MDS]/MPN with neutrophilia" per World Health Organization [WHO]) is a MDS/MPN overlap disorder featuring dysplastic neutrophilia and circulating myeloid precursors. Both manifest with frequent hepatosplenomegaly and less commonly, bleeding, with high rates of leukemic transformation and death.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!